See more : Bilot Oyj (BILOT.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Taiwan Liposome Company, Ltd. (TLC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taiwan Liposome Company, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Danske Invest Europa Akk klasse DKK h (DKIEUADKKH.CO) Income Statement Analysis – Financial Results
- Erste Group Bank AG (EBS.VI) Income Statement Analysis – Financial Results
- Rothschild & Co SCA (ROTH.PA) Income Statement Analysis – Financial Results
- Curtiss-Wright Corporation (CW) Income Statement Analysis – Financial Results
- FutureFuel Corp. (FF) Income Statement Analysis – Financial Results
Taiwan Liposome Company, Ltd. (TLC)
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 101.93M | 209.14M | 62.32M | 49.64M | 41.67M | 59.77M | 95.92M | 158.64M | 240.66M | 78.23M | 36.65M | 25.97M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 101.93M | 209.14M | 62.32M | 49.64M | 41.67M | 59.77M | 95.92M | 158.64M | 240.66M | 78.23M | 36.65M | 25.97M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 967.50M | 860.42M | 832.58M | 813.25M | 736.88M | 634.85M | 664.45M | 470.24M | 374.58M | 257.33M | 209.57M | 166.40M |
| General & Administrative | 145.77M | 166.38M | 147.74M | 134.87M | 141.49M | 138.32M | 102.99M | 98.14M | 55.85M | 46.03M | 45.28M | 46.68M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 145.77M | 166.38M | 147.74M | 134.87M | 141.49M | 138.32M | 102.99M | 98.14M | 55.85M | 46.03M | 45.28M | 46.68M |
| Other Expenses | -28.23M | -16.05M | -26.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.09B | 1.01B | 954.09M | 948.12M | 878.37M | 773.17M | 767.43M | 568.38M | 430.44M | 303.36M | 254.85M | 213.09M |
| Cost & Expenses | 1.09B | 1.01B | 954.09M | 948.12M | 878.37M | 773.17M | 767.43M | 568.38M | 430.44M | 303.36M | 254.85M | 213.09M |
| Interest Income | 1.19M | 7.40M | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 472.00K | 311.00K | 298.00K | 258.00K |
| Interest Expense | 16.35M | 23.66M | 9.89M | 3.39M | 2.94M | 2.59M | 1.31M | 1.63M | 2.14M | 2.39M | 2.31M | 1.21M |
| Depreciation & Amortization | 56.17M | 71.40M | 47.46M | 52.50M | 75.24M | 60.93M | 51.51M | 30.18M | 25.73M | 23.12M | 19.07M | 20.91M |
| EBITDA | -909.66M | -708.34M | -843.36M | -817.13M | -745.57M | -611.72M | -579.75M | -368.80M | -159.01M | -191.08M | -168.69M | -161.82M |
| EBITDA Ratio | -892.45% | -338.69% | -1,353.19% | -1,646.28% | -1,789.06% | -1,023.43% | -604.40% | -232.47% | -66.07% | -244.25% | -460.26% | -623.22% |
| Operating Income | -983.11M | -801.61M | -891.77M | -898.49M | -836.70M | -713.40M | -671.51M | -409.74M | -189.78M | -225.13M | -218.20M | -187.12M |
| Operating Income Ratio | -964.51% | -383.29% | -1,430.85% | -1,810.19% | -2,007.72% | -1,193.55% | -700.06% | -258.27% | -78.86% | -287.77% | -595.36% | -720.67% |
| Total Other Income/Expenses | 933.00K | -1.80M | -8.94M | 25.48M | 12.95M | 38.16M | 38.94M | 9.12M | 2.90M | 8.54M | 28.13M | 3.18M |
| Income Before Tax | -982.18M | -803.40M | -900.71M | -873.01M | -823.75M | -675.24M | -632.57M | -400.61M | -186.88M | -216.59M | -190.07M | -183.94M |
| Income Before Tax Ratio | -963.60% | -384.15% | -1,445.20% | -1,758.86% | -1,976.66% | -1,129.70% | -659.46% | -252.52% | -77.65% | -276.86% | -518.61% | -708.41% |
| Income Tax Expense | 1.13M | 4.12M | 867.00K | 951.00K | 563.00K | 450.00K | 292.00K | 359.00K | 251.00K | 394.00K | 142.00K | 127.00K |
| Net Income | -983.31M | -807.52M | -901.57M | -873.96M | -824.32M | -675.69M | -632.86M | -400.97M | -187.13M | -216.99M | -190.21M | -184.07M |
| Net Income Ratio | -964.71% | -386.12% | -1,446.59% | -1,760.78% | -1,978.01% | -1,130.46% | -659.77% | -252.75% | -77.76% | -277.36% | -519.00% | -708.90% |
| EPS | -24.89 | -24.64 | -28.75 | -31.50 | -29.78 | -24.50 | -23.08 | -16.44 | -9.50 | -14.60 | -18.18 | -17.92 |
| EPS Diluted | -24.89 | -24.64 | -28.75 | -31.50 | -29.78 | -24.50 | -23.08 | -16.44 | -9.50 | -14.60 | -18.18 | -17.92 |
| Weighted Avg Shares Out | 39.51M | 32.77M | 31.36M | 27.74M | 27.68M | 27.58M | 27.42M | 24.39M | 19.70M | 14.86M | 10.46M | 10.27M |
| Weighted Avg Shares Out (Dil) | 39.51M | 32.77M | 31.36M | 27.74M | 27.68M | 27.58M | 27.42M | 24.39M | 19.70M | 14.86M | 10.46M | 10.27M |
Glad® and T-Boz Bring `90s Nostalgia to the Household Cleaning Experience
The founding TLC member teams up with the fragrance-forward brand to celebrate scents that take you back OAKLAND, Calif. , July 22, 2024 /PRNewswire/ -- Glad, the nation's leading household waste solutions brand, is partnering with Tionne Watkins, better known...
Life Science Equipment Market to be Worth $97.96 Billion by 2031 - Exclusive Report by Meticulous Research®
REDDING, Calif., May 20, 2024 /PRNewswire/ -- According to a new market research report titled, 'Life Science Equipment Market Size, Share, Forecast, & Trends Analysis By Technology (Spectroscopy, Microscopy, Chromatography (HPLC, GC, TLC), PCR, Immunoassay, Sequencing, Flow Cytometry, Microarray, Centrifuge)...
Samsung Electronics Begins Industry’s First Mass Production of 9th-Gen V-NAND
Industry-leading bit density with about 50% increase compared to previous generation Productivity for the V-NAND’s groundbreaking double-stack structure enhanced through advanced ‘channel hole etching’ technology SEOUL, South Korea–(BUSINESS WIRE)–#9thGeneration–Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today...
Samsung Electronics Begins Industry’s First Mass Production of 9th-Gen V-NAND
Industry-leading bit density with about 50% increase compared to previous generation Productivity for the V-NAND’s groundbreaking double-stack structure enhanced through advanced ‘channel hole etching’ technology SEOUL, South Korea–(BUSINESS WIRE)–#9thGeneration–Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today...
Highlights of Dr. David Hunter's Oral Presentation at ACR's Late Breaking Abstracts Session
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks
Shining a light on School Nutrition and the Lunchtime Heroes that make it happen
BAKERSFIELD, Calif., Nov. 3, 2022 (SEND2PRESS NEWSWIRE) — Todd Linsky Consulting (TLC) announced today: TLC-Todd-versations, in collaboration with the Chef Ann Foundation, brings you stories from across our great country on positive changes to the school nutrition landscape, “Todd-versations Lunchtime...
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares
TAIPEI, Taiwan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company or TLC (Nasdaq: TLC, TWO: 4152, “the Company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that it has notified...
TLC Reports Second Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30,...
Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop
Looking for the next AMC, retail investors are on the hunt for the next squeeze. Here are five short squeeze stocks to watch this week.
Source: https://incomestatements.info
Category: Stock Reports